Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):982-989. doi: 10.1051/medsci/2019194. Epub 2020 Jan 6.

[Anti-tumor monoclonal antibodies: new insights to elicit a long-term immune response].

[Article in French; Abstract available in French from the publisher]

Author information

1
Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Royaume-Uni.
2
IRCM, Institut de Recherche en Cancérologie de Montpellier, Inserm U1194, Université Montpellier, Institut Régional du Cancer de Montpellier, F-34298 Montpellier, France.

Abstract

in English, French

Tumor-targeting monoclonal antibodies (mAbs) are now widely used for the treatment of cancer patients and their numbers are constantly increasing. Over the past ten years, numerous studies have demonstrated that the anti-tumor role of these antibodies far exceeds that of passive therapies as it was initially described, with the possibility of recruiting innate immune cells to promote activation of the early stages of immune response and to generate a long-term protective anti-tumor memory immune response. Understanding these mechanisms has recently led to the clinical development of a new generation of anti-tumor antibodies modified to increase their ability to interact with immune cells. Finally, the first preclinical and clinical studies have recently demonstrated the interest of developing therapeutic combinations combining anti-tumor mAbs with immune-, chemo- or radiotherapy, to reinforce their immunomodulatory potential and ensure effective and durable anti-tumor protection.

PMID:
31903903
DOI:
10.1051/medsci/2019194

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center